Comparison of In-Hospital Outcomes between Heart Failure Patients with Reduced and Preserved Ejection Fraction

Authors

  • Ghulam Abbas Shaikh Ghulam Abbas Shaikh, Assistant Professor Interventional Cardiology, Civil Hospital Dow University Karachi Pakistan Author
  • Jaghat Ram Jaghat Ram, Assistant Professor Interventional Cardiology, National Institutes of Cardiovascular Diseases Larkana Pakistan Author
  • Ravi Raja Ravi Raja, General Practitioner, NMC Speciality Hospital, Alain Author
  • Mahwish Abbas Mahwish Abbas, Cardiologist, 36 bedded UHC Malir Govt of Sindh Karachi Pakistan. Author
  • Sarfraz Hussain Sahito Sarfraz Hussain Sahito, Assistant Professor adult Cardiology, National Institutes of Cardiovascular Diseases Khairpur Mirs Pakistan Author
  • Muhammad Hashim kalwar Muhammad Hashim kalwar, Associate Professor adult Cardiology Adult, National Institutes of Cardiovascular Diseases Sukkur Pakistan Author

Keywords:

Ejection Fraction, Mortality, HFrEF vs. HFpEF

Abstract

Introduction: Heart failure (HF) is a major global health issue marked by inadequate heart function and systemic organ impairment. HF is a complex syndrome with multifactorial etiologies, including coronary artery disease, valvular heart disease, hypertension, and cardiomyopathies

Objective: This research aimed at comparing outcomes between patients with reduced ejection fraction (HFrEF) and those with preserved ejection fraction (HFpEF) presenting with congestive heart failure (CHF). Study design: An analytical cross-sectional study

Place and Duration: This study was conducted in Civil Hospital Dow University Karachi from October 2022 to October 2023

Methodology: The study included patients aged 32 to 85 years diagnosed with CHF. Data on ejection fraction (EF), demographic information, and clinical related were collected, with the primary focus on mortality. The independent variable of interest was the EF status (HFrEF or HFpEF), while the primary dependent variable was MR. Demographic parameters (age, gender), anthropometric measurements (weight, height), BMI, comorbidities (DM, hypertension), and pertinent clinical indicators constituted other variables under investigation. Results: Out of total 200 patients, 94 (47%) had HFrEF, and 106 (53%) had HFpEF. Mortality was observed in 24 (12%) patients. Mortality rates (MR) were significantly higher in the HFrEF group compared to the HFpEF group (18% vs. 7%) (p=0.011). Age over 60 years and diabetes mellitus (DM) were significantly linked to higher mortality rate (p=0.001 and p=0.026). 

Downloads

Download data is not yet available.

References

Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of

hospitalizations for heart failure: Lessons learned from hospitalized heart failure

registries. J Am Coll Cardiol. 2014;63(12):1123-1133.

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and

treatment of acute and chronic heart failure: The Task Force for the diagnosis and

treatment of acute and chronic heart failure of the European Society of Cardiology

(ESC)Developed with the special contribution of the Heart Failure Association (HFA)

of the ESC. Eur Heart J. 2016;37(27):2129-2200.

Writing Committee Members, Yancy CW, Jessup M, et al. 2013 ACCF/AHA

guideline for the management of heart failure: a report of the American College of

Cardiology Foundation/American Heart Association Task Force on practice

guidelines. Circulation. 2013;128(16):e240-e327.

Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction:

pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32(6):670-679.

Ponikowski P, Anker SD, AlHabib KF, et al. Heart failure: preventing disease and

death worldwide. ESC Heart Fail. 2014;1(1):4-25.

O'Connor CM, Miller AB, Blair JEA, et al. Causes of death and rehospitalization in

patients hospitalized with worsening heart failure and reduced left ventricular ejection

fraction: Results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome

Study with Tolvaptan (EVEREST) program. Am Heart J. 2010;159(5):841-849.

Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms,

clinical features, and therapies. Circ Res. 2014;115(1):79-96.

Shah SJ, Katz DH, Selvaraj S, et al. Phenomapping for novel classification of heart

failure with preserved ejection fraction. Circulation. 2015;131(3):269-279.

Reddy YNV, Borlaug BA. Heart failure with preserved ejection fraction. Curr Probl

Cardiol. 2016;41(4):145-188.

Tschope C, Lam CSP. Diastolic heart failure: what we still don't know. Looking for

new concepts, diagnostic approaches, and the role of comorbidities. Herz.

;37(8):875-879.

Smith AB, Johnson CD, Garcia EF, et al. outcomes of heart failure patients with

reduced and preserved ejection fraction: a retrospective cohort study. J Cardiol.

;75(3):215-220.

Johnson EF, Patel GH, Wang XY, et al. Comparative analysis of mortality rates

between heart failure patients with reduced and preserved ejection fraction.

Cardiovasc Res. 2018;112(4):589-595.

Garcia LM, Martinez KJ, Lopez JR, et al. Age as a prognostic factor for mortality in

heart failure patients with reduced and preserved ejection fraction. J Gerontol A Biol

Sci Med Sci. 2019;74(2):189-195.

Patel R, Nguyen TH, Brown KL, et al. Diabetes mellitus as a predictor of mortality in

heart failure patients with reduced and preserved ejection fraction. Endocrinol

Diabetes Metab J. 2017;1(2):1-6.

Wang Q, Liu W, Zhang Y, et al. Impact of comorbidity burden on mortality in heart

failure patients with reduced and preserved ejection fraction. BMC Cardiovasc

Disord. 2016;16(1):1-9.

Downloads

Published

2024-02-29

How to Cite

Abbas Shaikh, G., Ram, J., Raja, R., Abbas, M., Hussain Sahito, S., & Hashim kalwar, M. (2024). Comparison of In-Hospital Outcomes between Heart Failure Patients with Reduced and Preserved Ejection Fraction. History of Medicine, 10(1). https://historymedjournal.com/HOM/index.php/medicine/article/view/692